Skip to main content
Clinical Epigenetics logoLink to Clinical Epigenetics
. 2022 Mar 9;14:36. doi: 10.1186/s13148-022-01256-0

Correction to: ZMYND10, an epigenetically regulated tumor suppressor, exerts tumor-suppressive functions via miR145-5p/NEDD9 axis in breast cancer

Yan Wang 1,#, Liangying Dan 1,2,#, Qianqian Li 1, Lili Li 3, Lan Zhong 3, Bianfei Shao 1, Fang Yu 1, Sanxiu He 1, Shaorong Tian 1, Jin He 1, Qian Xiao 1, Thomas C Putti 4, Xiaoqian He 1, Yixiao Feng 1, Yong Lin 5, Tingxiu Xiang 1,
PMCID: PMC8908647  PMID: 35264219

Correction to: Clinical Epigenetics (2019) 11:184 10.1186/s13148-019-0785-z

Following the publication of this article, the authors noted that images of SK-BR-3 group in Fig. 9B were misplaced by mistake. The corrected Fig. 9B and corresponding bar graph is now shown in this correction. The authors confirm that the conclusions of this paper are not affected, and sincerely apologize for this error and any inconvenience that may have caused.

Fig. 9.

Fig. 9

Transfected with miR145-5p inhibitor in MDA-MB231 and SK-BR-3 cell partially reversed ZMYND10’s effect on migration and invasion. a Effect of miR145-5p inhibitor transfection on the migration of MDA-MB231 and SK-BR-3 cells. b Effect of miR145-5p inhibitor transfection on the invasion of MDA-MB231 and SK-BR-3 cells. **p < 0.01; ***p < 0.001

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yan Wang and Liangying Dan have contributed equally to this work.


Articles from Clinical Epigenetics are provided here courtesy of BMC

RESOURCES